A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eric S,Rovner

第一单位： Department of Urology, Medical University of South Carolina, Charleston, SC, USA. Electronic address: rovnere@musc.edu.

作者： Eric S,Rovner ^[1] ; Kevin V,Carlson ^[2] ; Anna S,Deal ^[3] ; Kavita V,Nair ^[4] ; Eva E,Oakkar ^[5] ; Julie,Park ^[5] ; Eric,Gemmen ^[5] ; Rita M,Kristy ^[6] ; Katherine L,Gooch ^[7] ; Carol R,Schermer ^[7]

作者单位： Department of Urology, Medical University of South Carolina, Charleston, SC, USA. Electronic address: rovnere@musc.edu. ^[1] Section of Urology, University of Calgary, Calgary, AB, Canada. ^[2] IPC - Inpatient Consultants - The Hospitalist Company, Johnson City, TN, USA. ^[3] Center for Pharmaceutical Outcomes Research, Department of Clinical Pharmacy, University of Colorado, Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. ^[4] IQVIA, Durham, NC, USA. ^[5] Medical Affairs, Astellas Pharma Global Development, Inc., Northbrook, IL, USA. ^[6] Medical Affairs, Americas, Astellas Pharma Global Development, Inc., Northbrook, IL, USA. ^[7]

关键词 Antimuscarinic Comparative effectiveness research Mirabegron Overactive bladder Patient-reported outcomes Registry